AR130938A1 - Terapia con células t car dirigidas a bcma contra el mieloma múltiple - Google Patents
Terapia con células t car dirigidas a bcma contra el mieloma múltipleInfo
- Publication number
- AR130938A1 AR130938A1 ARP230102927A ARP230102927A AR130938A1 AR 130938 A1 AR130938 A1 AR 130938A1 AR P230102927 A ARP230102927 A AR P230102927A AR P230102927 A ARP230102927 A AR P230102927A AR 130938 A1 AR130938 A1 AR 130938A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- mrd
- vhh domain
- negative state
- responsiveness
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un método para evaluar la capacidad de respuesta de un sujeto a un tratamiento que comprende células T que expresan un receptor de antígeno quimérico (CAR) dirigido a BCMA bivalente, que comprende administrar al sujeto las células T, y evaluar la capacidad de respuesta del sujeto al tratamiento basado en la duración del tiempo que el sujeto mantiene un estado negativo de enfermedad residual mínima (MRD). Reivindicación 1: Un método para evaluar la capacidad de respuesta de un sujeto a un tratamiento que comprende células T que expresan un receptor de antígeno quimérico (CAR) dirigido a BCMA bivalente, caracterizado porque comprende: (a) administrar al sujeto las células T; (b) medir la duración del tiempo que el sujeto mantiene un estado negativo de enfermedad residual mínima (MRD); y (c) evaluar la capacidad de respuesta del sujeto al tratamiento basado en que (i) el estado negativo para MRD se mantiene por menos de 6 meses; (ii) el estado negativo para MRD se mantiene durante al menos 6 meses y menos de 12 meses; o (iii) el estado negativo para MRD se mantiene durante al menos 12 meses; en donde el CAR dirigido a BCMA bivalente comprende un dominio de unión al antígeno extracelular que comprende un primer dominio VHH y un segundo dominio VHH, un dominio transmembrana, y un dominio de señalización intracelular, en donde el primer dominio VHH comprende una CDR1, una CDR2, y una CDR3 como se establece en el dominio VHH que comprende la secuencia de aminoácidos de la SEQ ID Nº 2, y el segundo dominio VHH comprende una CDR1, una CDR2, y una CDR3 como se expone en el dominio VHH que comprende la secuencia de aminoácidos de la SEQ ID Nº 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263421740P | 2022-11-02 | 2022-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130938A1 true AR130938A1 (es) | 2025-02-05 |
Family
ID=90931497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102927A AR130938A1 (es) | 2022-11-02 | 2023-11-01 | Terapia con células t car dirigidas a bcma contra el mieloma múltiple |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240156962A1 (es) |
| EP (1) | EP4612187A1 (es) |
| JP (1) | JP2026501059A (es) |
| KR (1) | KR20250103641A (es) |
| AR (1) | AR130938A1 (es) |
| AU (1) | AU2023373360A1 (es) |
| IL (1) | IL320528A (es) |
| MX (1) | MX2025005091A (es) |
| TW (1) | TW202430551A (es) |
| WO (1) | WO2024097738A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023500338A (ja) | 2019-11-05 | 2023-01-05 | ヤンセン バイオテツク，インコーポレーテツド | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
| CN120505394A (zh) * | 2025-07-04 | 2025-08-19 | 奥创新药(杭州)医药技术有限公司 | 一种细胞在药物分子筛选中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP2023500338A (ja) * | 2019-11-05 | 2023-01-05 | ヤンセン バイオテツク，インコーポレーテツド | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
-
2023
- 2023-11-01 AR ARP230102927A patent/AR130938A1/es unknown
- 2023-11-01 AU AU2023373360A patent/AU2023373360A1/en active Pending
- 2023-11-01 JP JP2025524544A patent/JP2026501059A/ja active Pending
- 2023-11-01 EP EP23886920.0A patent/EP4612187A1/en active Pending
- 2023-11-01 IL IL320528A patent/IL320528A/en unknown
- 2023-11-01 KR KR1020257015147A patent/KR20250103641A/ko active Pending
- 2023-11-01 WO PCT/US2023/078327 patent/WO2024097738A1/en not_active Ceased
- 2023-11-01 TW TW112142072A patent/TW202430551A/zh unknown
- 2023-11-01 US US18/499,720 patent/US20240156962A1/en active Pending
-
2025
- 2025-04-30 MX MX2025005091A patent/MX2025005091A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4612187A1 (en) | 2025-09-10 |
| WO2024097738A1 (en) | 2024-05-10 |
| US20240156962A1 (en) | 2024-05-16 |
| KR20250103641A (ko) | 2025-07-07 |
| TW202430551A (zh) | 2024-08-01 |
| MX2025005091A (es) | 2025-06-02 |
| AU2023373360A1 (en) | 2025-06-12 |
| JP2026501059A (ja) | 2026-01-14 |
| IL320528A (en) | 2025-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130938A1 (es) | Terapia con células t car dirigidas a bcma contra el mieloma múltiple | |
| Ullah et al. | Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy | |
| Dai et al. | Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease | |
| Lynch et al. | Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection | |
| PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos | |
| Brindley et al. | Triggering the measles virus membrane fusion machinery | |
| Booker et al. | Presynaptic GABAB receptors functionally uncouple somatostatin interneurons from the active hippocampal network | |
| TWI613215B (zh) | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 | |
| NO20076673L (no) | Antistoffer rettet mot CD20 og anvendelser derav | |
| HRP20200376T1 (hr) | Receptori t-stanica protiv ljudskog papiloma virusa 16e7 | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| CN107849096A (zh) | 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子 | |
| EP3747908A1 (fr) | Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs | |
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| Agrawal et al. | A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| JP2012527904A (ja) | 自己免疫性ｔ細胞の単離および処理のためのペプトイドリガンド | |
| Daugan et al. | Type I interferon impairs specific antibody responses early during establishment of LCMV infection | |
| JOP20220099A1 (ar) | علاج الورم النقوي المتعدد باستخدام خلايا car تائية تستهدف bcma | |
| JP2022535550A (ja) | 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用 | |
| EP3886905A1 (en) | Bispecific antibody for membrane clearance of target receptors | |
| RU2008139602A (ru) | Гуманизированное моноклональное анти-cd20-антитело | |
| Eichholz et al. | Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers | |
| JP2025123308A (ja) | ＴＲＢＣβ抗体コンジュゲート | |
| EP2872158A1 (en) | Vaccine and uses thereof |